NO20062561L - Kinoliner nyttige for behandling av kardiovaskulaere sykdommer - Google Patents
Kinoliner nyttige for behandling av kardiovaskulaere sykdommerInfo
- Publication number
- NO20062561L NO20062561L NO20062561A NO20062561A NO20062561L NO 20062561 L NO20062561 L NO 20062561L NO 20062561 A NO20062561 A NO 20062561A NO 20062561 A NO20062561 A NO 20062561A NO 20062561 L NO20062561 L NO 20062561L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- cardiovascular diseases
- useful
- quinolines useful
- quinolines
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 title 1
- 150000003248 quinolines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52900903P | 2003-12-12 | 2003-12-12 | |
US60029604P | 2004-08-10 | 2004-08-10 | |
PCT/US2004/041399 WO2005058834A2 (en) | 2003-12-12 | 2004-12-10 | Quinolines useful in treating cardiovascular disease |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062561L true NO20062561L (no) | 2006-09-08 |
Family
ID=34704262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062561A NO20062561L (no) | 2003-12-12 | 2006-06-02 | Kinoliner nyttige for behandling av kardiovaskulaere sykdommer |
Country Status (18)
Country | Link |
---|---|
US (1) | US7576215B2 (ko) |
EP (2) | EP2284157A1 (ko) |
JP (1) | JP2007516258A (ko) |
KR (1) | KR20070001922A (ko) |
AR (1) | AR047329A1 (ko) |
AU (1) | AU2004298486A1 (ko) |
BR (1) | BRPI0417543A (ko) |
CA (1) | CA2547518A1 (ko) |
CR (1) | CR8410A (ko) |
EC (1) | ECSP066635A (ko) |
IL (1) | IL175892A0 (ko) |
NO (1) | NO20062561L (ko) |
PA (1) | PA8619901A1 (ko) |
PE (1) | PE20050676A1 (ko) |
RU (1) | RU2006124843A (ko) |
SV (1) | SV2005001973A (ko) |
TW (1) | TW200529845A (ko) |
WO (1) | WO2005058834A2 (ko) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003082802A1 (en) * | 2002-03-27 | 2003-10-09 | Smithkline Beecham Corporation | Acid and ester compounds and methods of using the same |
US7247748B2 (en) * | 2002-03-27 | 2007-07-24 | Smithkline Corporation | Amide compounds and methods of using the same |
US7365085B2 (en) * | 2002-03-27 | 2008-04-29 | Smithkline Beecham Corporation | Compounds and methods |
WO2003082192A2 (en) * | 2002-03-27 | 2003-10-09 | Smithkline Beecham Corporation | Certain pharmaceutically useful substituted aminoalkyl heterocycles |
US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
EP2253315A1 (en) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
JP4793692B2 (ja) * | 2004-04-26 | 2011-10-12 | 小野薬品工業株式会社 | 新規なblt2介在性疾患、blt2結合剤および化合物 |
WO2005115145A2 (en) * | 2004-05-20 | 2005-12-08 | Wyeth | Quinone substituted quinazoline and quinoline kinase inhibitors |
US7989179B2 (en) * | 2005-06-28 | 2011-08-02 | Daiichi Sankyo Company, Limited | LXR ligand testing method |
GB0521083D0 (en) * | 2005-10-17 | 2005-11-23 | Novartis Ag | Organic compounds |
US20070093524A1 (en) * | 2005-10-25 | 2007-04-26 | Wyeth | 5-Lipoxygenase modulators |
US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
WO2008036238A2 (en) * | 2006-09-19 | 2008-03-27 | Wyeth | Use of lxr modulators for the prevention and treatment of skin aging |
JP2010503730A (ja) * | 2006-09-19 | 2010-02-04 | ワイス エルエルシー | 変形性関節症の治療のためのlxrアゴニストの使用 |
TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
US8450336B2 (en) * | 2006-12-14 | 2013-05-28 | Nps Pharmaceuticals, Inc | Use of D-serine derivatives for the treatment of anxiety disorders |
US20090069373A1 (en) * | 2007-02-28 | 2009-03-12 | Wyeth | Quinoline Acids |
ES2320955B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
US20080221127A1 (en) * | 2007-03-08 | 2008-09-11 | Plexxikon Inc | Ppar active compounds |
ES2329639B1 (es) * | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
BRPI0812816B8 (pt) * | 2007-06-18 | 2021-05-25 | Richter Gedeon Nyrt | compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmos |
US8063220B2 (en) | 2007-06-22 | 2011-11-22 | Richter Gedeon Nyrt. | Sulfonyl-quinoline derivatives |
CA2705318C (en) | 2007-11-15 | 2013-12-31 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
JP5285709B2 (ja) | 2007-11-16 | 2013-09-11 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスの複製阻害薬 |
CA2710461A1 (en) * | 2007-12-21 | 2009-07-09 | Wyeth Llc | Benzimidazole compounds |
US20090209601A1 (en) * | 2008-02-15 | 2009-08-20 | Wyeth | Use of rxr agonists for the treatment of osteoarthritis |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) * | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
US8008306B2 (en) | 2008-04-30 | 2011-08-30 | Kowa Company, Ltd. | Quinoline compounds |
CN102105452A (zh) | 2008-05-29 | 2011-06-22 | 兴和株式会社 | 具有环状连接基的取代甲醇化合物 |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
MX2010014066A (es) * | 2008-06-16 | 2011-06-01 | Univ Tennessee Res Foundation | Compuestos para el tratamiento del cancer. |
JP2012503595A (ja) * | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | 代謝病の治療用の化合物 |
JP5281647B2 (ja) * | 2008-09-08 | 2013-09-04 | 日本曹達株式会社 | 含窒素ヘテロ環化合物およびその塩並びに農園芸用殺菌剤 |
WO2010054229A1 (en) * | 2008-11-07 | 2010-05-14 | Wyeth Llc | Quinoxaline-based lxr modulators |
RU2404971C2 (ru) * | 2008-12-02 | 2010-11-27 | ЗАО "Фарм-Синтез" | Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе |
CA2745787A1 (en) * | 2008-12-05 | 2010-06-10 | The Government Of The United States Of America D.B.A.The Department Of V Eterans Affairs | Compounds having antiparasitic or anti-infectious activity |
US8598354B2 (en) | 2008-12-05 | 2013-12-03 | University Of South Florida | Compounds having antiparasitic or anti-infectious activity |
WO2010125811A1 (ja) | 2009-04-29 | 2010-11-04 | 興和株式会社 | ヘテロ環リンカーを有するカルビノール化合物 |
EP2424843B1 (en) | 2009-04-30 | 2014-03-26 | Novartis AG | Imidazole derivatives and their use as modulators of cyclin dependent kinases |
WO2010151737A2 (en) * | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
WO2011109059A1 (en) | 2010-03-01 | 2011-09-09 | Gtx, Inc. | Compounds for treatment of cancer |
AU2011275347A1 (en) * | 2010-07-08 | 2013-02-07 | Wyeth Llc | Novel quinoline esters useful for treating skin disorders |
BR112013005425A2 (ko) | 2010-09-07 | 2018-05-02 | Snu R&Db Foundation | Three master teopin compounds and uses of these materials |
ES2379242B1 (es) * | 2010-09-28 | 2013-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromeno. |
CA2882292C (en) | 2012-08-13 | 2023-10-17 | The Rockefeller University | Treatment and diagnosis of melanoma |
AR093017A1 (es) | 2012-10-16 | 2015-05-13 | Janssen Pharmaceutica Nv | MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO |
JP6250686B2 (ja) | 2012-10-16 | 2017-12-20 | ヤンセン ファーマシューティカ エヌ.ベー. | Rorγtのヘテロアリール結合させたキノリニルモジュレータ |
JP6251277B2 (ja) | 2012-10-16 | 2017-12-20 | ヤンセン ファーマシューティカ エヌ.ベー. | ROR−ガンマ−tのフェニル結合キノリニルモジュレーター |
CN103965105A (zh) * | 2013-01-29 | 2014-08-06 | 中山大学 | 苯乙烯基喹啉衍生物及其在治疗阿尔茨海默病症中的应用 |
WO2014123203A1 (ja) * | 2013-02-06 | 2014-08-14 | 京都薬品工業株式会社 | 糖尿病治療薬 |
WO2014138279A1 (en) | 2013-03-05 | 2014-09-12 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
ES2770727T3 (es) | 2013-10-15 | 2020-07-02 | Janssen Pharmaceutica Nv | Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t |
CA2926313A1 (en) | 2013-10-15 | 2015-04-23 | Kristi A. Leonard | Secondary alcohol quinolinyl modulators of roryt |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9624225B2 (en) | 2013-10-15 | 2017-04-18 | Janssen Pharmaceutica Nv | Quinolinyl modulators of RORγt |
EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
CN104036909B (zh) * | 2014-06-25 | 2016-09-28 | 桂林理工大学 | 磁性材料[Cu3(N3)6(DMF)2]n及合成方法 |
WO2016057454A1 (en) | 2014-10-06 | 2016-04-14 | The Johns Hopkins University | Targeting liver nuclear receptors as a treatment for wilson disease |
CN109069461A (zh) | 2016-01-11 | 2018-12-21 | 洛克菲勒大学 | 与髓源性抑制细胞相关的病症的治疗方法 |
EP3246028A1 (en) * | 2016-05-18 | 2017-11-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline compounds for increasing insuline release |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
AU2018265148A1 (en) * | 2017-05-12 | 2019-10-03 | Rti International | Diarylureas as CB1 allosteric modulators |
WO2019074241A1 (ko) * | 2017-10-11 | 2019-04-18 | 정원혁 | 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제 |
US11505559B2 (en) | 2017-10-30 | 2022-11-22 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors |
US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
CA3120970A1 (en) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
TW202128161A (zh) | 2019-10-18 | 2021-08-01 | 美國加利福尼亞大學董事會 | 用於靶向病原性血管之化合物及方法 |
WO2021096589A1 (en) * | 2019-11-15 | 2021-05-20 | Georgia State University Research Foundation, Inc. | Small molecules polymerase inhibitors |
CN114728875A (zh) | 2019-12-13 | 2022-07-08 | 因思博纳公司 | 金属盐及其用途 |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2962658D1 (en) | 1978-01-28 | 1982-06-24 | Croda Synthetic Chem Ltd | Process for the preparation of aromatic (b)-fused pyridines and novel thieno(b)pyridines |
US4407803A (en) | 1981-08-17 | 1983-10-04 | Abbott Laboratories | Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives |
DE3413078A1 (de) | 1984-04-06 | 1985-10-24 | Miles Laboratories, Inc., Elkhart, Ind. | Chromogene aminosaeure- und peptidester, verfahren zu deren herstellung, verwendung dieser verbindungen in analysenverfahren sowie mittel zum nachweis esterolytischer und/oder proteolytischer enzyme |
CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
US4761419A (en) | 1987-12-07 | 1988-08-02 | Warner-Lambert Company | 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
IL92544A0 (en) | 1988-12-08 | 1990-08-31 | Duphar Int Res | Piperazine derivatives,their preparation and pharmaceutical compositions containing them |
DE3905908A1 (de) * | 1989-02-25 | 1990-09-06 | Bayer Ag | Substituierte chinoline, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
DE3908298A1 (de) | 1989-03-14 | 1990-09-20 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-n,n'-sulfonylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
DE3916663A1 (de) | 1989-05-23 | 1990-11-29 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
DE3927369A1 (de) | 1989-08-19 | 1991-02-21 | Bayer Ag | Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe |
DE3927931A1 (de) | 1989-08-24 | 1991-02-28 | Bayer Ag | Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate |
DE3927930A1 (de) | 1989-08-24 | 1991-02-28 | Bayer Ag | Cyclisch substituierte (chinolin-2-yl-methoxy)phenyl-essig-saeure-derivate |
MX22406A (es) | 1989-09-15 | 1994-01-31 | Pfizer | Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat). |
DE3935139A1 (de) | 1989-10-21 | 1991-04-25 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-thioharnstoffe |
DE3935491A1 (de) | 1989-10-25 | 1991-05-02 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-carbonylharnstoffe |
JPH03181465A (ja) * | 1989-12-11 | 1991-08-07 | Takeda Chem Ind Ltd | キノリン誘導体 |
GB9113137D0 (en) | 1990-07-13 | 1991-08-07 | Ici Plc | Thioxo heterocycles |
JPH04182469A (ja) | 1990-11-16 | 1992-06-30 | Terumo Corp | 新規なチオエステル化合物 |
JP2696150B2 (ja) | 1991-02-05 | 1998-01-14 | 株式会社大塚製薬工場 | キノリン誘導体 |
US6004979A (en) | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
DE4105551A1 (de) | 1991-02-22 | 1992-08-27 | Bayer Ag | 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
DE4139751A1 (de) | 1991-12-03 | 1993-06-09 | Bayer Ag, 5090 Leverkusen, De | Thiazolyl substituierte chinolylmethoxyphenylessigsaeurederivate |
DE4112533A1 (de) | 1991-04-17 | 1992-10-22 | Bayer Ag | Verfahren zur herstellung von enantiomerenreinen substituierten (chinolin-2-yl-methoxy)phenyl-essigsaeuren |
WO1992019614A1 (en) * | 1991-04-26 | 1992-11-12 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)quinoline derivatives |
US5366987A (en) * | 1991-08-22 | 1994-11-22 | Warner-Lambert Company | Isoxazolyl-substituted alkyl amide ACAT inhibitors |
DE4128681A1 (de) | 1991-08-29 | 1993-03-04 | Bayer Ag | Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
JP3130342B2 (ja) | 1991-10-04 | 2001-01-31 | 日産化学工業株式会社 | 動脈硬化性血管内膜肥厚抑制薬 |
JPH05128327A (ja) | 1991-11-01 | 1993-05-25 | Mitsubishi Electric Corp | Icカード |
JPH05130897A (ja) | 1991-11-11 | 1993-05-28 | Terumo Corp | チオール化合物測定用試薬組成物 |
DE4139750A1 (de) | 1991-12-03 | 1993-06-09 | Bayer Ag, 5090 Leverkusen, De | Chinolylmethoxyphenylessigsaeure-acylamide und -harnstoffe |
DE4139749A1 (de) | 1991-12-03 | 1993-06-09 | Bayer Ag, 5090 Leverkusen, De | Chinolylmethoxyphenyl-essigsaeureamide |
IL104369A0 (en) * | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
US5183825A (en) | 1992-04-07 | 1993-02-02 | American Home Products Corporation | 4-arylmethyl-5-alkyl-3H-pyrazol-3-ones and hypoglycemic use |
EP0570112A1 (en) | 1992-04-23 | 1993-11-18 | Zeneca Limited | Cycloalkane derivatives |
DE4226519A1 (de) | 1992-08-11 | 1994-02-17 | Bayer Ag | 3-Substituierte Chinolylmethoxy-phenylessigsäurederivate |
JPH0692939A (ja) | 1992-09-16 | 1994-04-05 | Kyowa Hakko Kogyo Co Ltd | イミダゾール誘導体 |
DE4243279A1 (de) | 1992-12-21 | 1994-06-23 | Bayer Ag | Substituierte Triole |
ATE163412T1 (de) * | 1993-06-08 | 1998-03-15 | Sanofi Sa | Pyridazine als interleukin-1-beta verwandlungsenzym inhibitoren |
JPH0710870A (ja) | 1993-06-23 | 1995-01-13 | Asahi Glass Co Ltd | 新規アミノピリジン誘導体およびその塩 |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
WO1995007922A1 (en) * | 1993-09-17 | 1995-03-23 | Smithkline Beecham Corporation | Drug binding protein |
JPH0789957A (ja) | 1993-09-22 | 1995-04-04 | Nissan Chem Ind Ltd | ビフェニルメチルアミン誘導体 |
US5453509A (en) | 1993-10-08 | 1995-09-26 | Synaptic Pharmaceutical Corporation | Functionalization of acyl pyridinium salts |
DE4411657A1 (de) | 1994-04-02 | 1995-10-05 | Basf Ag | Verfahren zur Herstellung von 6-Hydroxymethylchinolinen |
FR2722198B1 (fr) | 1994-07-08 | 1996-10-04 | Pf Medicament | 1derives de silylmethyl-anilines, le2fabrication, et leur utilisation co |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
DE19500120A1 (de) | 1995-01-04 | 1996-07-11 | Bayer Ag | Neue acylierte Pseudopeptide mit trifluormethyl-subsstituiertem 2-Azabicyclooctan |
DE19500122A1 (de) | 1995-01-04 | 1996-07-11 | Bayer Ag | Neue Pseudopeptide mit trifluormethyl-substituierten 2-Azabicyclooctan |
US5650415A (en) * | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
US5837719A (en) * | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
DE19532714A1 (de) | 1995-09-05 | 1997-03-06 | Bayer Ag | Kombination von 5-Lipoxygenase- und Leukotriensynthese Inhibitoren mit Glucocorticosteroiden |
JPH1067658A (ja) | 1995-09-13 | 1998-03-10 | Takeda Chem Ind Ltd | 免疫抑制剤 |
ID16283A (id) | 1996-03-20 | 1997-09-18 | Astra Pharma Prod | Senyawa yang berguna dibidang farmasi |
WO1997044036A1 (en) | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors |
EP0808627A2 (de) | 1996-05-22 | 1997-11-26 | Hoechst Aktiengesellschaft | Verwendung nicht-peptidischer Bradykinin-Antagonisten zur Behandlung und Prävention von chronisch-fibrogenetischen Lebererkrankungen, akuten Lebererkrankungen und den damit verbundenen Komplikationen |
JPH101471A (ja) | 1996-06-13 | 1998-01-06 | Green Cross Corp:The | N−[(キノリン−2−イル)フェニル]スルホンアミド類の結晶およびその製造方法 |
WO1998014430A1 (fr) | 1996-10-02 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Derives de pyrimidine |
WO1998020007A1 (en) | 1996-11-06 | 1998-05-14 | Darwin Discovery Limited | Quinolines and their therapeutic use |
CA2279977A1 (en) | 1997-02-04 | 1998-08-06 | John S. Kiely | 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries |
DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
JP2002505689A (ja) | 1997-06-19 | 2002-02-19 | セプレイコー インコーポレイテッド | キノリン−インドール抗菌剤、それらに関する用途及び組成物 |
AR016294A1 (es) | 1997-07-02 | 2001-07-04 | Smithkline Beecham Corp | Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion |
US6538022B1 (en) | 1997-09-24 | 2003-03-25 | Orion Corporation | Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors) |
EP1047691A1 (en) | 1997-12-12 | 2000-11-02 | Smithkline Beecham Plc | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
ES2212971T3 (es) | 1999-11-30 | 2004-08-16 | Pfizer Products Inc. | Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa. |
EP1239855A4 (en) * | 1999-12-13 | 2004-04-21 | Merck & Co Inc | METHOD FOR PREVENTING AND TREATING ARTERIOSCLEROSIS |
GB0002032D0 (en) | 2000-01-28 | 2000-03-22 | Zeneca Ltd | Chemical compounds |
JP5491681B2 (ja) | 2000-02-04 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤 |
US6838467B2 (en) | 2000-02-24 | 2005-01-04 | Janssen Pharmaceutica N. V. | Dosing regimen |
AU2001252147A1 (en) | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations |
EP1261356A2 (en) | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
JP2003525255A (ja) | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤 |
CA2397349A1 (en) | 2000-02-29 | 2001-09-07 | Ivan David Horak | Farnesyl protein transferase inhibitor combinations with an her2 antibody |
WO2001064199A2 (en) | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with taxane compounds |
CA2397446A1 (en) | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica Inc. | Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
AU2001244167A1 (en) | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
WO2001070228A1 (en) | 2000-03-17 | 2001-09-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
WO2001070227A1 (en) | 2000-03-17 | 2001-09-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
JP2001261654A (ja) | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
US6495562B1 (en) | 2000-04-25 | 2002-12-17 | Abbott Laboratories | Naphthamidine urokinase inhibitors |
AU2001262984A1 (en) * | 2000-05-03 | 2001-11-12 | Tularik, Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
AU2001276716A1 (en) | 2000-08-08 | 2002-02-18 | Shionogi And Co., Ltd. | Cyclic amine derivatives and use thereof |
GB0023918D0 (en) | 2000-09-29 | 2000-11-15 | King S College London | Antiparasitic compounds |
DE60128936T2 (de) | 2000-10-12 | 2008-04-10 | Merck & Co, Inc. | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
AU2001296119A1 (en) | 2000-10-13 | 2002-04-22 | Astrazeneca Ab | Estrogen receptor-beta ligands |
CN100360550C (zh) | 2001-05-03 | 2008-01-09 | 芝加哥大学 | 肝脏x受体激动剂 |
JP2002371078A (ja) | 2001-06-12 | 2002-12-26 | Sankyo Co Ltd | キノリン誘導体及びキノロン誘導体 |
EP1270535A3 (de) | 2001-06-20 | 2004-02-18 | Clariant GmbH | Verfahren zur Herstellung von substituierten aromatischen Verbindungen |
FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
EP1426046A4 (en) * | 2001-09-14 | 2005-11-02 | Shionogi & Co | NEW USE OF TRICYCLIC COMPOUNDS |
AU2002336433A1 (en) * | 2001-10-08 | 2003-04-22 | Eli Lilly And Company | Tricyclic compounds useful for modulating lxr |
WO2003082198A2 (en) * | 2002-03-27 | 2003-10-09 | Smithkline Beecham Corporation | Methods of treatment with lxr modulators |
-
2004
- 2004-12-10 WO PCT/US2004/041399 patent/WO2005058834A2/en active Application Filing
- 2004-12-10 AU AU2004298486A patent/AU2004298486A1/en not_active Abandoned
- 2004-12-10 PE PE2004001236A patent/PE20050676A1/es not_active Application Discontinuation
- 2004-12-10 PA PA20048619901A patent/PA8619901A1/es unknown
- 2004-12-10 RU RU2006124843/04A patent/RU2006124843A/ru not_active Application Discontinuation
- 2004-12-10 TW TW093138244A patent/TW200529845A/zh unknown
- 2004-12-10 BR BRPI0417543-3A patent/BRPI0417543A/pt not_active IP Right Cessation
- 2004-12-10 SV SV2004001973A patent/SV2005001973A/es not_active Application Discontinuation
- 2004-12-10 EP EP10181673A patent/EP2284157A1/en not_active Withdrawn
- 2004-12-10 US US11/010,236 patent/US7576215B2/en not_active Expired - Fee Related
- 2004-12-10 EP EP04813688A patent/EP1692111A2/en not_active Withdrawn
- 2004-12-10 JP JP2006544016A patent/JP2007516258A/ja active Pending
- 2004-12-10 KR KR1020067014042A patent/KR20070001922A/ko not_active Application Discontinuation
- 2004-12-10 AR ARP040104624A patent/AR047329A1/es not_active Application Discontinuation
- 2004-12-10 CA CA002547518A patent/CA2547518A1/en not_active Abandoned
-
2006
- 2006-05-19 CR CR8410A patent/CR8410A/es not_active Application Discontinuation
- 2006-05-24 IL IL175892A patent/IL175892A0/en unknown
- 2006-06-02 NO NO20062561A patent/NO20062561L/no not_active Application Discontinuation
- 2006-06-12 EC EC2006006635A patent/ECSP066635A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP066635A (es) | 2006-10-25 |
KR20070001922A (ko) | 2007-01-04 |
WO2005058834A3 (en) | 2005-11-17 |
EP1692111A2 (en) | 2006-08-23 |
AU2004298486A1 (en) | 2005-06-30 |
JP2007516258A (ja) | 2007-06-21 |
US7576215B2 (en) | 2009-08-18 |
CA2547518A1 (en) | 2005-06-30 |
PE20050676A1 (es) | 2005-11-02 |
CR8410A (es) | 2006-10-04 |
AR047329A1 (es) | 2006-01-18 |
IL175892A0 (en) | 2006-10-05 |
SV2005001973A (es) | 2005-11-04 |
BRPI0417543A (pt) | 2007-03-27 |
TW200529845A (en) | 2005-09-16 |
EP2284157A1 (en) | 2011-02-16 |
PA8619901A1 (es) | 2005-11-25 |
RU2006124843A (ru) | 2008-01-20 |
US20050131014A1 (en) | 2005-06-16 |
WO2005058834A2 (en) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062561L (no) | Kinoliner nyttige for behandling av kardiovaskulaere sykdommer | |
NO20070933L (no) | Indazoler anvendbare i behandling av kardiovaskulaere sykdommer | |
NO20063479L (no) | Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer | |
WO2007079199A3 (en) | Substituted bis-amide metalloprotease inhibitors | |
NO20060230L (no) | Nye aminobenzofenonforbindelser | |
TW200510334A (en) | Preraration and use of aryl alkyl acid derivatives for the treatment of obesity | |
NO20092711L (no) | Metoder for anvendelse av cyclopaminanaloger | |
WO2005046603A3 (en) | Pyridine compounds | |
NO20062256L (no) | Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner | |
NO20084912L (no) | Bisykliske derivater som CETP-inhibitorer | |
NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
NO20052580D0 (no) | Blandinger for behandling av infeksjon av Flavivirida viruser | |
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
NO20072963L (no) | 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere | |
ATE433447T1 (de) | Pyrimiidinverbindungen | |
NO20076371L (no) | Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner | |
ATE486597T1 (de) | 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie | |
NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
MX2007011847A (es) | Derivados de pirimidindiona como antagonistas del receptor de procineticina 2. | |
ATE418554T1 (de) | 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen | |
NO20083923L (no) | Pyrazolkinoloner er potente parp-inhibitorer | |
EA200501928A1 (ru) | Пирролодигидроизохинолины как ингибиторы pde10 | |
NO20064344L (no) | Caspaseinhibitorer og anvendelser derav | |
BRPI0509660A (pt) | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |